



U.S. CONSUMER PRODUCT SAFETY COMMISSION

4330 EAST WEST HIGHWAY
BETHESDA, MARYLAND 20814-4408

Record of Commission Action Commissioners Voting by Ballot*

Commissioners Voting: Acting Chairman Robert S. Adler
 Commissioner Elliot F. Kaye
 Commissioner Dana Baiocco
 Commissioner Peter A. Feldman

ITEM:

Petition Requesting Exemption from Special Packaging Requirements of the Poison Prevention Packaging Act for XOFLUZA™ (Baloxavir marboxil)
(Briefing package dated October 28, 2020, OS No. 0034)

DECISION:

The Commission voted unanimously (4-0) to **not** approve the draft *Federal Register* notice inviting public comments for Petition PP 20-1, from Genentech, Inc., requesting that the Commission exempt the prescription drug, XOFLUZA™ (Baloxavir marboxil), from the special packaging requirements of the Poison Prevention Packaging Act (PPPA). Staff advised that all available information necessary for making the staff's technical decision under the PPPA was provided with the petition.

For the Commission:

Alberta E. Mills
Alberta E. Mills
Secretary

* Ballot vote due November 3, 2020